FDA Extends Nexplanon Use - Summary - MDSpire

FDA Extends Nexplanon Use

US study data showed zero pregnancies in years 4 and 5 of etonogestrel implant use.

  • By

  • Kathryn Wighton

  • January 20, 2026

  • 3 min

Share

Objective:

To extend the labeled duration of use of the etonogestrel implant (Nexplanon) for pregnancy prevention from three years to up to five years.

Key Findings:
  • Nexplanon is effective for up to five years with no pregnancies reported during years 4 and 5.
  • No new safety findings were observed during the extended use.
  • Changes in menstrual bleeding patterns were the most common adverse reaction leading to discontinuation.
Interpretation:

The updated label for Nexplanon reflects its efficacy and safety for a broader range of women, including those with higher BMIs.

Limitations:
  • The study was open-label and single-arm, which may introduce bias.
  • The long-term effects beyond five years are not evaluated.
Conclusion:

Nexplanon is now approved for pregnancy prevention for up to five years, enhancing contraceptive options for women.

Original Source(s)

FDA Extends Nexplanon Use

  • by Kathryn Wighton

  • January 20, 2026

Related Content

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

31 Live Births Reported Following Uterus Transplant

Single-center series details maternal, obstetric, and neonatal outcomes among recipients with uterine-factor infertility

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization